Abstract
The 2017 Workshop of the Society for Hematopathology/European Association for Haematopathology reviewed the role of genetic testing in the diagnosis of hematopoietic neoplasms, including non-acute leukemia myeloid malignancies. Methods: The workshop panel assigned 98 submitted cases to the category of non-acute leukemia myeloid neoplasms, of which 13 were selected for oral presentation. Results: Data from both conventional karyotyping and genetic sequencing had important impact on diagnosis, classification, and prognostication. However, some cases had genetic results that appeared discordant from the morphology and/or clinical features. Thus, the workshop underscored the need for careful management of genetic data by the pathologist and clinician, in the context of other findings. Conclusions: The workshop cases highlighted the significance of genetic aberrations in the diagnosis and treatment of non-acute leukemia myeloid neoplasms. Many genetic data have already been incorporated in the most recent World Health Organization classification, and undoubtedly they will factor increasingly in future classifications.
Original language | English (US) |
---|---|
Article number | aqz069 |
Pages (from-to) | 302-321 |
Number of pages | 20 |
Journal | American journal of clinical pathology |
Volume | 152 |
Issue number | 3 |
DOIs | |
State | Published - Aug 1 2019 |
Externally published | Yes |
Keywords
- Cytogenetics
- Molecular diagnostics
- Myelodysplastic syndrome
- Myeloproliferative neoplasm
- Targeted therapy
- WHO classification
ASJC Scopus subject areas
- Pathology and Forensic Medicine